Tolerability To Paracetamol and Preferential Cox-2 Inhibitors in Patients With Cross-Reactive Nonsteroidal Anti-Inflammatory Drugs Hypersensitivity
dc.authorid | Epozturk, Kursat/0000-0002-0839-8944 | |
dc.authorid | Tulumen Ozturk, Raziye/0000-0001-9503-661X | |
dc.authorid | Ekerbicer, Hasan Cetin/0000-0003-0064-3893 | |
dc.authorwosid | Ekerbiçer, Hasan Çetin/Hht-0237-2022 | |
dc.contributor.author | Terzioglu, Kadriye | |
dc.contributor.author | Sancar, Ozgur | |
dc.contributor.author | Ekerbicer, Hasan Cetin | |
dc.contributor.author | Ozturk, Raziye Tulumen | |
dc.contributor.author | Epozturk, Kursat | |
dc.date.accessioned | 2025-05-31T20:21:09Z | |
dc.date.available | 2025-05-31T20:21:09Z | |
dc.date.issued | 2020 | |
dc.department | Okan University | en_US |
dc.department-temp | [Terzioglu, Kadriye] Kartal Training & Res Hosp, Dept Allergy & Immunol, E5-Karayolu Cevizli Mevkii, TR-34890 Istanbul, Turkey; [Sancar, Ozgur; Ekerbicer, Hasan Cetin] Sakarya Univ, Dept Publ Hlth, Fac Med, Training & Res Hosp, Sakarya, Turkey; [Ozturk, Raziye Tulumen] Bursa State Hosp, Dept Allergy & Immunol, Bursa, Turkey; [Epozturk, Kursat] Okan Univ Hosp, Istanbul, Turkey | en_US |
dc.description | Epozturk, Kursat/0000-0002-0839-8944; Tulumen Ozturk, Raziye/0000-0001-9503-661X; Ekerbicer, Hasan Cetin/0000-0003-0064-3893 | en_US |
dc.description.abstract | Background: Acetylsalicylic acid/aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used drugs that may cause hypersensitivity reactions in a substantial proportion of patients. Physicians ought to be aware of these situations. Objective: We aimed to present the clinical characteristics and rates of tolerability to cyclooxygenase (COX)-2 inhibitor analgesics in patients who had admitted due to multiple cross-reactive type of NSAID hypersensitivity. Methods: The files of the patients who had admitted with multiple NSAIDs-induced symptoms were investigated retrospectively. Age, sex, underlying diseases, clinical manifestation, skin test results, and drug provocation test results were analyzed. Results: In 105 patients with multiple cross-reactive type of NSAID hypersensitivity, we found the rate of cross-reactivity to any of the relatively safe alternatives including paracetamol, meloxicam, and nimesulide to be 16.1%. The rate of cross-reactivity to these relatively safe drugs was significantly higher in patients with a history of anaphylaxis induced by NSAID intake (p= 0.006). Conclusion: The diagnosis of COX-1-mediated multiple NSAID hypersensitivity can be often established with a detailed history. Although rare, severe hypersensitivity reactions may be observed in these patients. Undesired situations for both patients and physicians may be avoided by testing relatively safe paracetamol and COX-2 inhibitors in experienced centers. | en_US |
dc.description.woscitationindex | Emerging Sources Citation Index | |
dc.identifier.doi | 10.5415/apallergy.2020.10.e29 | |
dc.identifier.issn | 2233-8276 | |
dc.identifier.issn | 2233-8268 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 32789114 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.uri | https://doi.org/10.5415/apallergy.2020.10.e29 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14517/7942 | |
dc.identifier.volume | 10 | en_US |
dc.identifier.wos | WOS:000557016600006 | |
dc.identifier.wosquality | N/A | |
dc.language.iso | en | en_US |
dc.publisher | Asia Pacific Assoc Allergy, Asthma & Clinical Immunology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Cyclooxygenase-2 Inhibitors | en_US |
dc.subject | Hypersensitivity | en_US |
dc.subject | Nonnarcotic Analgesics | en_US |
dc.subject | Nonsteroidal Anti-Inflammatory Agents | en_US |
dc.subject | Paracetamol | en_US |
dc.title | Tolerability To Paracetamol and Preferential Cox-2 Inhibitors in Patients With Cross-Reactive Nonsteroidal Anti-Inflammatory Drugs Hypersensitivity | en_US |
dc.type | Article | en_US |